{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:28:18Z","timestamp":1785788898287,"version":"3.56.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Foundation to Eradicate Duchenne Board","award":["1003037"],"award-info":[{"award-number":["1003037"]}]},{"name":"Arthritis","award":["20843"],"award-info":[{"award-number":["20843"]}]},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"BRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Training","award":["MR\/T008172\/1"],"award-info":[{"award-number":["MR\/T008172\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Vamorolone, a dissociated steroidal compound with reduced side effects, offers a promising alternative to traditional glucocorticoids for inflammatory diseases. Unlike conventional glucocorticoids, vamorolone lacks the hydroxyl or ketone groups required for metabolism by 11\u03b2-hydroxysteroid dehydrogenase type 1 (11\u03b2-HSD1), a key enzyme that modulates glucocorticoid activity. This study investigates vamorolone\u2019s resistance to 11\u03b2-HSD1 metabolism and assesses its therapeutic efficacy in the murine tumour necros factor-alpha-overexpressing (TNFtg) model of polyarthritis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>11\u03b2-HSD1 metabolism and action were examined in Hs68 and primary leucocyte culture. Vamorolone 20\u2009mg\/kg\/day, prednisolone (standard of care) or vehicle were administered by gavage to TNFtg or TNFtg 11\u03b2-HSD1 knock-out (TNFtg11BKOKO) animals. Body weight and disease severity were scored daily, and markers of inflammation, joint destruction and side effects assessed at day 56 of age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Vamorolone was entirely resistant to 11\u03b2-HSD1 metabolism in vitro. Vamorolone demonstrated comparable anti-inflammatory actions in TNFtg mice, with a comparable reduction in joint inflammation, serum interleukin-6 (IL-6) and synovitis relative to prednisolone. However, vamorolone-treated mice did not experience typical glucocorticoid side effects, including adrenal atrophy, body weight reduction, muscle wasting or inhibition of anabolic bone metabolism. These benefits persisted in 11\u03b2-HSD1 knockout mice, indicating that the efficacy of vamorolone is largely independent of 11\u03b2-HSD1 metabolism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The findings suggest that at the effective anti-inflammatory dose examined in this study, vamorolone possesses a reduced profile of deleterious systemic effects relative to prednisolone. Whilst highlighting its potential for broader clinical application in inflammatory conditions, it remains unclear whether these side effects would remain mild at markedly higher doses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf129","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:20:55Z","timestamp":1741004455000},"page":"4371-4381","source":"Crossref","is-referenced-by-count":13,"title":["Vamorolone: a novel metabolism resistant steroid that suppresses joint destruction in chronic polyarthritis with reduced systemic side effects"],"prefix":"10.1093","volume":"64","author":[{"given":"Ana","family":"Crastin","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Shanker","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Sagmeister","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Systems Science, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Systems Science, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth G","family":"Lavery","sequence":"additional","affiliation":[{"name":"Department of Biosciences, Centre for Systems Health and Integrated Metabolic Research, Nottingham Trent University , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Aging, University of Birmingham , Birmingham,","place":["UK"]},{"name":"Sandwell and West Birmingham NHS Trust , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan S","family":"Hardy","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Birmingham , Birmingham,","place":["UK"]},{"name":"Department of Metabolism and Systems Science, University of Birmingham , Birmingham,","place":["UK"]},{"name":"MRC Arthritis Research UK Centre for Musculoskeletal Ageing Research, University of Birmingham , Birmingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2025070205013798400_keaf129-B1","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","article-title":"Glucocorticoid resistance in inflammatory diseases","volume":"373","author":"Barnes","year":"2009","journal-title":"Lancet"},{"key":"2025070205013798400_keaf129-B2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr.21796","article-title":"Prevalence of oral glucocorticoid usage in the United States: a general population perspective","volume":"65","author":"Overman","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025070205013798400_keaf129-B3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2133.2007.07950.x","article-title":"Corticosteroid-induced clinical adverse events: frequency, risk factors and patient\u2019s opinion","volume":"157","author":"Fardet","year":"2007","journal-title":"Br J Dermatol"},{"key":"2025070205013798400_keaf129-B4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","article-title":"Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases","volume":"16","author":"Hardy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025070205013798400_keaf129-B5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1677\/joe.1.06019","article-title":"11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action","volume":"186","author":"Draper","year":"2005","journal-title":"J Endocrinol"},{"key":"2025070205013798400_keaf129-B6","doi-asserted-by":"crossref","first-page":"7828","DOI":"10.3390\/ijms22157828","article-title":"Global deletion of 11\u03b2-HSD1 prevents muscle wasting associated with glucocorticoid therapy in polyarthritis","volume":"22","author":"Webster","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025070205013798400_keaf129-B7","doi-asserted-by":"crossref","first-page":"E2482","DOI":"10.1073\/pnas.1323681111","article-title":"11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess","volume":"111","author":"Morgan","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025070205013798400_keaf129-B8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13075-019-1972-1","article-title":"11beta-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy","volume":"21","author":"Fenton","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025070205013798400_keaf129-B9","doi-asserted-by":"crossref","first-page":"e208112","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with duchenne muscular dystrophy: a randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"2025070205013798400_keaf129-B10","doi-asserted-by":"crossref","first-page":"e1003222","DOI":"10.1371\/journal.pmed.1003222","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study","volume":"17","author":"Smith","year":"2020","journal-title":"PLoS Med"},{"key":"2025070205013798400_keaf129-B11","doi-asserted-by":"crossref","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025070205013798400_keaf129-B12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: a Randomized Clinical Trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"key":"2025070205013798400_keaf129-B13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00011-016-0956-8","article-title":"VBP15, a novel dissociative steroid compound, reduces NFkappaB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis","volume":"65","author":"Damsker","year":"2016","journal-title":"Inflamm Res"},{"key":"2025070205013798400_keaf129-B14","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/emmm.201302621","article-title":"VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects","volume":"5","author":"Heier","year":"2013","journal-title":"EMBO Mol Med"},{"key":"2025070205013798400_keaf129-B15","doi-asserted-by":"crossref","first-page":"e63871","DOI":"10.1371\/journal.pone.0063871","article-title":"VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice","volume":"8","author":"Damsker","year":"2013","journal-title":"PLoS One"},{"key":"2025070205013798400_keaf129-B16","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00011-019-01279-z","article-title":"Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset","volume":"68","author":"Damsker","year":"2019","journal-title":"Inflamm Res"},{"key":"2025070205013798400_keaf129-B17","doi-asserted-by":"crossref","first-page":"24285","DOI":"10.1073\/pnas.2006890117","article-title":"Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment","volume":"117","author":"Liu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025070205013798400_keaf129-B18","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","article-title":"VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid","volume":"21","author":"Reeves","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"2025070205013798400_keaf129-B19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/annrheumdis-2020-218493","article-title":"Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids","volume":"80","author":"Fenton","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025070205013798400_keaf129-B20","doi-asserted-by":"crossref","first-page":"7334","DOI":"10.3390\/ijms23137334","article-title":"11beta-hydroxysteroid dehydrogenase type 1 within osteoclasts mediates the bone protective properties of therapeutic corticosteroids in chronic inflammation","volume":"23","author":"Fenton","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025070205013798400_keaf129-B21","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J"},{"key":"2025070205013798400_keaf129-B22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0023677217707985","article-title":"TNFalpha depleting therapy improves fertility and animal welfare in TNFalpha-driven transgenic models of polyarthritis when administered in their routine breeding","volume":"52","author":"Naylor","year":"2018","journal-title":"Lab Anim"},{"key":"2025070205013798400_keaf129-B23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/path.4806","article-title":"11beta-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation","volume":"240","author":"Hardy","year":"2016","journal-title":"J Pathol"},{"key":"2025070205013798400_keaf129-B24","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/ar1993","article-title":"Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation","volume":"8","author":"Hardy","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2025070205013798400_keaf129-B25","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800186","article-title":"Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy","author":"Heier","year":"2019","journal-title":"Life Sci Alliance"},{"key":"2025070205013798400_keaf129-B26","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"key":"2025070205013798400_keaf129-B27","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/art.34414","article-title":"Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells","volume":"64","author":"Ahasan","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025070205013798400_keaf129-B28","doi-asserted-by":"crossref","first-page":"100687","DOI":"10.1016\/j.jbc.2021.100687","article-title":"Repression of transcription by the glucocorticoid receptor: a parsimonious model for the genomics era","volume":"296","author":"Gerber","year":"2021","journal-title":"J Biol Chem"},{"key":"2025070205013798400_keaf129-B29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12012-012-9188-5","article-title":"Expression of glucocorticoid-induced leucine zipper (GILZ) in cardiomyocytes","volume":"13","author":"Aguilar","year":"2013","journal-title":"Cardiovasc Toxicol"},{"key":"2025070205013798400_keaf129-B30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10571-014-0133-y","article-title":"VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis","volume":"35","author":"Dillingham","year":"2015","journal-title":"Cell Mol Neurobiol"},{"key":"2025070205013798400_keaf129-B31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4049\/jimmunol.167.1.30","article-title":"11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages","volume":"167","author":"Thieringer","year":"2001","journal-title":"J Immunol"},{"key":"2025070205013798400_keaf129-B32","doi-asserted-by":"crossref","first-page":"103263","DOI":"10.1016\/j.jaut.2024.103263","article-title":"Inflammation dynamically regulates steroid hormone metabolism and action within macrophages in rheumatoid arthritis","volume":"147","author":"Martin","year":"2024","journal-title":"J Autoimmun"},{"key":"2025070205013798400_keaf129-B33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1359\/jbmr.2002.17.6.979","article-title":"Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure","volume":"17","author":"Cooper","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2025070205013798400_keaf129-B34","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1210\/jc.2015-1516","article-title":"Gender-specific differences in skeletal muscle 11beta-HSD1 expression across healthy aging","volume":"100","author":"Hassan-Smith","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2025070205013798400_keaf129-B35","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41467-023-36541-w","article-title":"11beta-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial","volume":"14","author":"Othonos","year":"2023","journal-title":"Nat Commun"},{"key":"2025070205013798400_keaf129-B36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13075-019-1962-3","article-title":"Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis","volume":"21","author":"Fenton","year":"2019","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf129\/62826253\/keaf129.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4371\/62826253\/keaf129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/7\/4371\/62826253\/keaf129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:01:49Z","timestamp":1751446909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/7\/4371\/8102198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4,2]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf129","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,4,2]]}}}